Be Biopharma (Series A)
Funding Details
- Awarder
- Inbox
- Date Award
- June 09, 2025
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $82,000,000
Company Info
- Founding Year
- 2020
- Traction
- Lead program BE-101 for Hemophilia B enters the clinic, and second development candidate BE-102 is unveiled.
- Organizations Involved
- Seattle Children's Research Institute
- Company Description
- Be Biopharma is a leader in the discovery and development of engineered B Cell Medicines (BCMs) to dramatically improve the lives of patients who are living with Hemophilia B and other genetic diseases, cancer, and other serious conditions.
- Market
- Healthcare
- Location
- Cambridge, MA, USA
- Coinvestors
- ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers Squibb, Takeda Ventures